238 related articles for article (PubMed ID: 25038230)
21. Sensitivity of glioma and fetal brain cell lines to natural killer cytolysis in a monolayer assay.
Kazimer RM; Whisler RL; Stephens RE; Pearl DK; Yates AJ
J Neurooncol; 1989 Jul; 7(2):145-50. PubMed ID: 2778490
[TBL] [Abstract][Full Text] [Related]
22. Harnessing the immune system against human glioma.
Dhodapkar KM; Banerjee D; Steinman RM
Ann N Y Acad Sci; 2005 Dec; 1062():13-21. PubMed ID: 16461784
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone enhances natural killer cell activity against glioma.
Shimizu K; Adachi K; Teramoto A
J Nippon Med Sch; 2005 Dec; 72(6):335-40. PubMed ID: 16415513
[TBL] [Abstract][Full Text] [Related]
24. The innate immune response in the central nervous system and its role in glioma immune surveillance.
Friese MA; Steinle A; Weller M
Onkologie; 2004 Oct; 27(5):487-91. PubMed ID: 15585981
[TBL] [Abstract][Full Text] [Related]
25. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.
Matsuda M; Nimura K; Shimbo T; Hamasaki T; Yamamoto T; Matsumura A; Kaneda Y
J Neurooncol; 2011 May; 103(1):19-31. PubMed ID: 20730616
[TBL] [Abstract][Full Text] [Related]
26. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity.
Radosavljevic G; Jovanovic I; Majstorovic I; Mitrovic M; Lisnic VJ; Arsenijevic N; Jonjic S; Lukic ML
Clin Exp Metastasis; 2011 Jun; 28(5):451-62. PubMed ID: 21442355
[TBL] [Abstract][Full Text] [Related]
27. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
Murphy KA; Erickson JR; Johnson CS; Seiler CE; Bedi J; Hu P; Pluhar GE; Epstein AL; Ohlfest JR
J Immunol; 2014 Jan; 192(1):224-33. PubMed ID: 24293627
[TBL] [Abstract][Full Text] [Related]
28. [Effects of interferons on syngeneic murine malignant glioma-specific killer T cell].
Yamasaki T; Yamashita J; Handa H; Namda Y; Hanaoka M
No Shinkei Geka; 1983 Oct; 11(10):1059-67. PubMed ID: 6196674
[TBL] [Abstract][Full Text] [Related]
29. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
30. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
31. Proteomic comparison of 3D and 2D glioma models reveals increased HLA-E expression in 3D models is associated with resistance to NK cell-mediated cytotoxicity.
He W; Kuang Y; Xing X; Simpson RJ; Huang H; Yang T; Chen J; Yang L; Liu E; He W; Gu J
J Proteome Res; 2014 May; 13(5):2272-81. PubMed ID: 24742303
[TBL] [Abstract][Full Text] [Related]
32. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
[TBL] [Abstract][Full Text] [Related]
33. Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.
Lowenstein PR; Baker GJ; Castro MG
Oncoimmunology; 2014 Nov; 3(11):e965573. PubMed ID: 25941594
[TBL] [Abstract][Full Text] [Related]
34. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood galectin-1-expressing T and natural killer cells in normal pregnancy and preeclampsia.
Molvarec A; Blois SM; Stenczer B; Toldi G; Tirado-Gonzalez I; Ito M; Shima T; Yoneda S; Vásárhelyi B; Rigó J; Saito S
Clin Immunol; 2011 Apr; 139(1):48-56. PubMed ID: 21292557
[TBL] [Abstract][Full Text] [Related]
36. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
37. Immunological surveillance against DNA-virus-transformed cells: correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents.
Cook JL; Lewis AM
J Virol; 1987 Jul; 61(7):2155-61. PubMed ID: 3495670
[TBL] [Abstract][Full Text] [Related]
38. [Effects of adult thymectomy on the growth of 203-glioma in mice--analysis of T cell subpopulation in tumor immunology].
Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
No To Shinkei; 1982 Nov; 34(11):1067-75. PubMed ID: 6984337
[TBL] [Abstract][Full Text] [Related]
39. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
Yamasaki T
Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
[No Abstract] [Full Text] [Related]
40. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Crane CA; Han SJ; Barry JJ; Ahn BJ; Lanier LL; Parsa AT
Neuro Oncol; 2010 Jan; 12(1):7-13. PubMed ID: 20150362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
